More recently, a study of Serbian subjects [106] confirmed that homozygous carriers of the GSTO2*N142D variant have an increased risk of ovarian cancer, whereas carriers of the H4 haplotype (i.e., GSTO1*A variant allele and GSTO2*A wild-type allele) have a lower OC risk. This evidence concerns the gene GSTO2 and ovarian cancer.